Virtual event attendees will gain a holistic view of cell therapy from beginning to end, including perspectives from industry leaders as well a patient who has benefitted from the therapy.
The format will consist of panel discussions delving into several areas including:
Where the field of cell therapy is headed, including new modalities, common challenges to avoid, and cutting edge technologies
Manufacturability including supply chain challenges, time-to-market, value for money, need for collaboration and lessons learned from the scale-up of antibody products
A leukaemia patient and his drug developer share their unique perspective and how their journeys converged.
Matthew Durdy - Chief Executive Officer, Cell & Gene Therapy Catapult